Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients with Follicular Lymphoma and Marginal Zone Lymphoma
- ClinicalTrials.gov Identifier: NCT03919175
- Protocol Number: 19-011
- Principal Investigator: Jon Arnason
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required